Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs
| Autor: | Vin Tangpricha, H. Maehr, Min Yao, L. Adorini, M. Uskokovic, Michael F. Holick, M. Michael Wolfe, Catherine S. Spina, W. Zhou |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Calcitriol Ratón Colorectal cancer Endocrinology Diabetes and Metabolism Clinical Biochemistry Molecular Conformation chemistry.chemical_element Calcium Biochemistry vitamin D deficiency Mice Endocrinology Equivalent Internal medicine Tumor Cells Cultured medicine Vitamin D and neurology Animals Vitamin D Molecular Biology Mice Inbred BALB C Binding Sites business.industry Body Weight Cell Biology Vitamin D Deficiency medicine.disease Ultraviolet B radiation chemistry Colonic Neoplasms Sunlight Molecular Medicine business medicine.drug |
| Zdroj: | The Journal of Steroid Biochemistry and Molecular Biology. 97:111-120 |
| ISSN: | 0960-0760 |
| Popis: | It has been recognized that people who live at higher latitudes and who are vitamin D deficient are at higher risk of dying from many common cancers including colon cancer. To evaluate the role of vitamin D deficiency on colon tumor growth, Balb/c adult male mice were fed either a vitamin D sufficient or vitamin D deficient diet for 10 weeks. Mice were arranged into groups of six and each animal received subcutaneously 10(4) MC-26 cells in the posterior trunk. The tumor size was recorded daily. By day 9 there was a significant difference in tumor volume between the vitamin D sufficient and vitamin D deficient mice. By day 18 the vitamin D deficient animals had a tumor size that was 56% larger compared to the animals that were vitamin D sufficient. To determine whether treatment with active vitamin D analogs could further decrease colon tumor growth in a vitamin D sufficient state, groups of mice were treated with the novel 19-nor-Gemini compounds. The mice were fed a low calcium diet. Twenty-four hours after tumor implantation, the mice received, three times weekly, one of the vitamin D analogs or the vehicle. The group that received Gemini 1,25-dihydroxy-21(3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyl)-19-nor-20S-cholecalciferol (3) showed a dose-dependent decrease in tumor volume. On day 19, at the dose level of 0.02microg molar equivalents (E), the tumor volume was reduced by 41% when compared to the control group. At the same time point, the hexadeuterated analog 1,25-dihydroxy-21(3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyl)-26,27-hexadeutero-19-nor-20S-cholecalciferol (4), administered at the 10-fold lower dose of 0.002microgE, showed a 52% reduction in tumor volume (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect